Evidence map›Paper›PMID 39654280›Full record

Trial reportDrug and alcohol review2025

What hepatology clinicians and their patients with alcohol-related liver disease think of wearable alcohol biosensors to aid abstinence from alcohol: A qualitative study.

Andrea DiMartini, Jaideep Behari, Jon Punzi, Michael Dunn, Ramon Bataller, John M Jakicic, Mary McNulty, Ryan C Young, Mary Amanda Dew

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03533660 (Alcohol Biosensor Monitoring for Alcoholic Liver Disease), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03533660 nacompletednot on this map

Alcohol Biosensor Monitoring for Alcoholic Liver Disease

TypeinterventionalSponsorUniversity of PittsburghRan2018 to 2021Enrolled33ConditionsAlcohol Use, UnspecifiedArmsFeedback, Enhanced Usual Care
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea DiMartiniDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-4883-121X
Jaideep BehariDepartment of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jon PunziDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Michael DunnClinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ramon BatallerDepartment of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
John M JakicicDepartment of Internal Medicine, Division of Physical Activity and Weight Management, University of Kansas Medical Center, Kansas City, Missouri, USA.
Mary McNultyDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ryan C YoungDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Mary Amanda DewDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Funding

Alcohol Biosensor Monitoring for Alcoholic Liver DiseaseR21AA025730 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DIMARTINI, ANDREA FRANCES · 2018 to 2019
$409k
NIAAA NIH HHS R21 AA025730
6 · The paper itself

Abstract

introductionWe aimed to determine acceptability and feasibility of innovative wearable alcohol biosensor monitors (ABM) for patients with alcohol-related liver disease (ALD) and their clinicians.

methodsPatients and clinicians at a tertiary care centre participated in qualitative interviews on usability, acceptability, feasibility, efficiency/effectiveness, impact of device on behaviour/clinical practice and preferences/barriers. Interviews were audiotaped, transcribed and coded using a constant comparison method for category themes.

resultsPatients (n = 23) were 56% female, mean 44 years old, 87% White, with moderate-severe liver disease. Some felt the ABMs appearance was unappealing; others felt it provided an opportunity for openness and education of others. While some found it feasible to wear, others felt it was unrealistic to wear 24/7. Importantly, there were many positive themes on effectiveness/efficiency-participants felt the ABM could better record their alcohol use and patterns of use than they could remember. Patients felt wearing the ABM motivated abstinence, gave accountability and was a source of security. Clinicians (n = 13) were mostly hepatologists (77%), seeing on average 38 ALD patients/month. Clinicians felt seeing patterns and amounts of alcohol use could inform clinical decision making and treatments but expressed concern over the volume and complexity of data. DISCUSSION AND

conclusionsPerspectives on ABMs for managing ALD were mixed among patients and providers. Future device designs may overcome acceptability barriers due to device appearance. However, for clinicians, the logistics of data gathering plus the complexity and volume of data produced by the ABM device requires considerable thought to make this an efficient tool for clinical use. CLINICALTRIALS: gov identifier NCT03533660: Alcohol biosensor monitoring for alcohol liver disease.

Indexed as

Alcohol AbstinenceAttitude of Health PersonnelBiosensing TechniquesGastroenterologistsLiver Diseases, AlcoholicWearable Electronic DevicesAdultFemaleHumansMaleMiddle AgedQualitative Researchacceptabilityalcohol‐related liver diseasefeasibilitywearable alcohol biosensors

Identifiers

PMID39654280
PMCPMC11813684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.